Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating costs | 0.04 | 0.05 | 0.06 | 0.04 | 0.07 | 0.06 | 0.07 | 0.11 | 0.03 | 0.02 | 0.07 | 0.02 |
| EBITDA | -0.04 | -0.05 | -0.06 | -0.04 | -0.07 | -0.06 | -0.07 | -0.11 | -0.03 | -0.02 | -0.07 | -0.02 |
| EBITDA margin % | ||||||||||||
| Depreciation & amortisation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Finance costs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non-operating income | 0.03 | 0.03 | 0.02 | 0.01 | 0.56 | 0.00 | 0.09 | 1.00 | 0.05 | 0.06 | 0.11 | 0.09 |
| Pre-tax profit | -0.01 | -0.02 | -0.04 | -0.03 | 0.49 | -0.06 | 0.02 | 0.89 | 0.02 | 0.04 | 0.04 | 0.07 |
| Effective tax rate % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 24.72% | 0.00% | 0.00% | -1,450.00% | 114.29% |
| Profit after tax | -0.01 | -0.02 | -0.04 | -0.03 | 0.48 | -0.06 | 0.02 | 0.67 | 0.01 | 0.04 | 0.62 | -0.02 |
| Earnings per share (Rs) | -0.02 | -0.03 | -0.07 | -0.05 | 0.81 | -0.10 | 0.01 | 0.47 | 0.01 | 0.03 | 0.43 | -0.01 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating costs | 0.13 | 0.17 | 0.29 | 0.26 | 0.18 | 0.16 | 0.16 | 0.17 | 0.19 | 0.25 | 0.25 | 0.14 |
| EBITDA | -0.13 | -0.17 | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.25 | -0.14 |
| EBITDA margin % | ||||||||||||
| Depreciation & amortisation | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Finance costs | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non-operating income | 0.06 | 0.17 | -3.42 | -0.07 | -0.12 | -0.07 | -3.70 | 0.07 | 0.13 | 0.66 | 1.24 | 0.31 |
| Pre-tax profit | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.23 | -3.86 | -0.10 | -0.06 | 0.41 | 0.99 | 0.17 |
| Effective tax rate % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -57.58% | ||
| Profit after tax | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.10 | -0.06 | 0.40 | 1.56 | 0.65 |
| Earnings per share (Rs) | -0.12 | 0.00 | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.10 | 0.28 | 1.09 | 0.46 |
| Paid out as dividend % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Revenue CAGR | % | % | % | % | ||
| Profit CAGR | 38% | 77% | 131% | -41% | ||
| Share price CAGR | 16% | 44% | 45% | -34% | ||
| Average return on equity | 0% | 2% | 3% | 6% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net block (property, plant) | 0.01 | 5.25 | 5.94 | 2.53 | 2.53 | 2.52 | 2.51 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Capital work in progress | 5.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.51 | 0.51 | 0.54 | 1.15 | 0.96 | 0.43 | 0.37 | 0.31 | 0.43 | 0.61 | 21.36 | 24.24 |
| Current & other assets | 0.23 | 0.93 | 0.29 | 1.07 | 1.07 | 1.16 | 1.21 | 0.95 | 0.69 | 0.71 | 4.25 | 3.15 |
| Total assets | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
| Share capital | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 13.97 | 13.97 |
| Reserves & surplus | -0.06 | -0.13 | -0.09 | -4.29 | -4.62 | -5.14 | -5.14 | -5.30 | -5.43 | -5.31 | 11.46 | 10.84 |
| Total debt | 0.14 | 0.27 | 0.31 | 0.00 | 0.10 | 0.17 | 0.18 | 0.03 | 0.02 | 0.10 | 0.16 | 0.00 |
| Other liabilities & provisions | 0.02 | 0.02 | 0.02 | 2.51 | 2.55 | 2.55 | 2.52 | 0.01 | 0.01 | 0.01 | 0.02 | 2.58 |
| Equity + liabilities | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.26 | 0.06 | 0.00 | 1.44 | -0.30 | -0.38 | -0.40 | -4.01 | -0.15 | 0.00 | 0.40 | 0.71 |
| Investing cash flow | -0.33 | -0.05 | 0.02 | -1.20 | 0.28 | 0.39 | 0.53 | 3.81 | -0.12 | 0.08 | 0.34 | -2.38 |
| Free cash flow (after capex) | 0.24 | -3.21 | 0.00 | 1.14 | -0.30 | -0.38 | -0.40 | -4.01 | -0.15 | 0.00 | 0.40 | 0.71 |
| Financing cash flow | 0.00 | 0.00 | 0.00 | 0.00 | -0.16 | -0.06 | -0.07 | 0.33 | 0.06 | -0.06 | 2.08 | -0.62 |
| Net change in cash | -0.07 | 0.01 | 0.02 | 0.23 | -0.18 | -0.05 | 0.06 | 0.13 | -0.20 | 0.01 | 2.82 | -2.29 |
| Cash conversion (OCF / EBITDA) % | -236% | -46% | 0% | -497% | 115% | 211% | 250% | 2,506% | 88% | 0% | -160% | -284% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on capital employed % | -0.45% | -1.05% | -1.49% | -6.01% | -8.47% | -2.80% | -5.75% | -7.07% | -12.61% | -13.11% | -0.97% | 3.93% |
| Receivable days | ||||||||||||
| Inventory days | ||||||||||||
| Payable days | ||||||||||||
| Cash cycle (days) | ||||||||||||
| Working capital days |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter group % | 42.67% | 42.67% | 42.67% | 42.67% | 20.71% | 10.60% | 0.20% | 0.20% | 0.08% | 0.08% | 0.00% | 0.00% |
| Retail & others % | 57.33% | 57.33% | 57.33% | 57.32% | 79.30% | 89.39% | 99.80% | 99.80% | 99.92% | 99.92% | 100.00% | 100.00% |
| Shareholder count | 6,647 | 6,628 | 6,770 | 6,794 | 6,902 | 7,461 | 7,638 | 7,532 | 7,431 | 7,431 | 7,226 | 7,326 |
Fundamentals
Market value₹ 38.7 Cr.
Last price₹ 27.0
P/E (trailing)59.6
Book value / share₹ 17.3
Return on capital3.93 %
Return on equity6.21 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)%
Profit CAGR (TTM)-41%
Standalone figures.
Valuation
Market capRs 39 Cr
Enterprise valueRs 39 Cr
P/E (TTM)60.24x
Price to book1.58x
EV / EBITDA226.97x
EV / EBIT226.97x
Price to cash flow55.15x
Earnings yield1.66%
P/E, 3-year average96.16x
P/B, 3-year average4.05x
P/E, 5-year average96.16x
P/B, 5-year average3.57x
Profitability
ROE6.21%
ROCE3.93%
ROA5.89%
ROE, 3-year average1.35%
ROCE, 3-year average0.69%
ROA, 3-year average1.33%
ROE, 5-year average-59.84%
ROCE, 5-year average-55.83%
ROA, 5-year average-29.68%
ROIC (approx.)1.11%
Tax rate-57.58%
Other income / net worth5.00%
Growth
Profit growth (latest year)290.00%
Profit growth QoQ-103.23%
Profit growth YoY (latest quarter)-102.99%
Per share
EPS (TTM)Rs 0.45
EPS (latest year)Rs 1.09
EPS (latest quarter)Rs -0.01
EPS, 3-year averageRs 0.42
EPS, 5-year averageRs -1.09
Book value per shareRs 17.29
Cash flow per shareRs 0.49
Leverage
Cash and bankRs 1 Cr
Net debtRs -1 Cr
Net debt / EBITDA-3.35x
Owners' fund to total sources90.58%
Cash flow
Operating cash flow (latest year)Rs 1 Cr
Investing cash flow (latest year)Rs -2 Cr
Financing cash flow (latest year)Rs -1 Cr
Net change in cash (latest year)Rs -2 Cr
Statement figures
Operating profit (latest quarter)Rs -0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs 0 Cr
Profit before tax (TTM)Rs 0 Cr
Tax (latest year)Rs -1 Cr
Net profit (TTM)Rs 1 Cr
Net profit (latest year)Rs 2 Cr
Net profit (latest quarter)Rs -0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 1 Cr
Share capitalRs 14 Cr
ReservesRs 11 Cr
Shareholders' fundsRs 25 Cr
Total assetsRs 27 Cr
InvestmentsRs 24 Cr
ReceivablesRs 1 Cr
Other liabilitiesRs 3 Cr
Shares outstanding (crore)1.44
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 1.58 is at the 13th percentile (median 5.44).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524516 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +9.0% | -2.8% | +11.8 pts |
| 1 month | +138.7% | -6.8% | +145.5 pts |
| 3 months | -31.8% | -7.6% | -24.2 pts |
| 3 years | +200.8% | +14.2% | +186.6 pts |
| 5 years | +524.3% | +27.9% | +496.4 pts |
Red flags
F-score 5 of 6| explain | Share dilution Share count up 0% in a year, 144% in three |
| look | Profit leans on other income Other income was 125% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹0 Cr.
Net loss ₹0 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Bacil Pharma Ltd?
Bacil Pharma Ltd (524516) has a market capitalisation of Rs 38.7 Cr. at the 2026-10-01 close.
What is the P/E ratio of Bacil Pharma Ltd?
Bacil Pharma Ltd trades at a P/E of 59.6 on trailing twelve-month profit, at the 2026-10-01 close.
What were Bacil Pharma Ltd's latest quarterly results?
In the Jun 2026 quarter, Bacil Pharma Ltd sales was Rs 0 Cr with a net loss of Rs 0 Cr.